Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

By HEOR Staff Writer

April 5, 2023

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and non-surgical clinical services with world-class healthcare quality for patients who require hematopoietic stem cell transplantation for the treatment of blood diseases. To date, 13 cancer patients and one MS female patient have been treated by ADSCC under the AD-BMT programme.

Reference url

Recent Posts

Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy

By João L. Carapinha

March 20, 2026

Novo Nordisk announced the Wegovy HD approval by the US Food and Drug Administration (FDA) for Wegovy® HD (semaglutide injection 7.2 mg), a higher-dose formulation showing superior weight loss over the existing 2.4 mg dose in adults with obesity. In the STEP UP trial, this new dose delivered an a...
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal Cord Injury Treatment
China's National Medical Products Administration (NMPA) has approved the world's first invasive brain-computer interface medical device for market entry. Developed by Borui Kang Medical Technology (Shanghai) Co.,...
Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Disease

By João L. Carapinha

March 19, 2026

HPV vaccine effectiveness is demonstrated in new clinical and real-world data from Merck, showcasing the sustained protection of GARDASIL®9 (9-valent Human Papillomavirus [HPV] vaccine) and GARDASIL® (4-valent HPV vaccine) against HPV-related cancers and diseases. Key findings include vaccine eff...